Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys

• Main Authors: Galler R., Marchevsky R.S., Caride E., Almeida L.F.C., Yamamura A.M.Y., Jabor A.V., Motta M.C.A., Bonaldo M.C., Coutinho E.S.F., Freire M.S.
• Format: Article
• Language: English
• Published: Associação Brasileira de Divulgação Científica 2005-01-01
• Series: Brazilian Journal of Medical and Biological Research
• Subjects: YF 17D virus recombinants; Dengue vaccine; Immunogenicity; Attenuation; Rhesus monkeys
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005001200012

A chimeric yellow fever (YF)-dengue serotype 2 (dengue 2) virus was constructed by replacing the premembrane and envelope genes of the YF 17D virus with those from dengue 2 virus strains of Southeast Asian genotype. The virus grew to high titers in Vero cells and, after passage 2, was used for immunogenicity and attenuation studies in rhesus monkeys. Subcutaneous immunization of naive rhesus monkeys with the 17D-D2 chimeric virus induced a neutralizing antibody response associated with the protection of 6 of 7 monkeys against viremia by wild-type dengue 2 virus. Neutralizing antibody titers to dengue 2 were significantly lower in YF-immune animals than in YF-naive monkeys and protection against challenge with wild-type dengue 2 virus was observed in only 2 of 11 YF-immune monkeys. An anamnestic response to dengue 2, indicated by a sharp increase of neutralizing antibody titers, was observed in the majority of the monkeys after challenge with wild-type virus. Virus attenuation was demonstrated using the standard monkey neurovirulence test. The 17D-D2 chimera caused significantly fewer histological lesions than the YF 17DD virus. The attenuated phenotype could also be inferred from the limited viremias compared to the YF 17DD vaccine. Overall, these results provide further support for the use of chimeric viruses for the development of a new live tetravalent dengue vaccine.